Literature DB >> 20921207

Colorectal cancer molecular biology moves into clinical practice.

Colin C Pritchard1, William M Grady.   

Abstract

The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next major advance in clinical medicine. This is no more evident than in the recent advances in testing of colorectal cancers for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, genetic mechanisms of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers) are examined.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20921207      PMCID： PMC3006043          DOI： 10.1136/gut.2009.206250

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  109 in total

1.  A stochastic carcinogenesis model incorporating multiple types of genomic instability fitted to colon cancer data.

Authors:  Mark P Little; Paolo Vineis; Guangquan Li
Journal:  J Theor Biol       Date:  2008-05-29       Impact factor: 2.691

2.  Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation- status.

Authors:  Stine A Danielsen; Guro E Lind; Merete Bjørnslett; Gunn I Meling; Torleiv O Rognum; Sverre Heim; Ragnhild A Lothe
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

3.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Authors:  Ludovic Barault; Céline Charon-Barra; Valérie Jooste; Mathilde Funes de la Vega; Laurent Martin; Patrick Roignot; Patrick Rat; Anne-Marie Bouvier; Pierre Laurent-Puig; Jean Faivre; Caroline Chapusot; Francoise Piard
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

Review 4.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

5.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

Review 6.  Genomic and epigenetic instability in colorectal cancer pathogenesis.

Authors:  William M Grady; John M Carethers
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

7.  A simplified, noninvasive stool DNA test for colorectal cancer detection.

Authors:  Steven Itzkowitz; Randall Brand; Lina Jandorf; Kris Durkee; John Millholland; Linda Rabeneck; Paul C Schroy; Stephen Sontag; David Johnson; Sanford Markowitz; Lawrence Paszat; Barry M Berger
Journal:  Am J Gastroenterol       Date:  2008-08-27       Impact factor: 10.864

8.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

9.  Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.

Authors:  Katsuhiko Nosho; Natsumi Irahara; Kaori Shima; Shoko Kure; Gregory J Kirkner; Eva S Schernhammer; Aditi Hazra; David J Hunter; John Quackenbush; Donna Spiegelman; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  PLoS One       Date:  2008-11-12       Impact factor: 3.240

10.  Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.

Authors:  Evangelia Razis; Evangelos Briasoulis; Eleni Vrettou; Dimosthenis V Skarlos; Dimitrios Papamichael; Ioannis Kostopoulos; Epaminontas Samantas; Ioannis Xanthakis; Mattheos Bobos; Eleni Galanidi; Maria Bai; Ioanna Gikonti; Alona Koukouma; Georgia Kafiri; Pavlos Papakostas; Konstantine T Kalogeras; Paris Kosmidis; George Fountzilas
Journal:  BMC Cancer       Date:  2008-08-13       Impact factor: 4.430
View more
  132 in total

1.  No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections.

Authors:  Teppei Morikawa; Kaori Shima; Aya Kuchiba; Mai Yamauchi; Noriko Tanaka; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Mohan Brahmandam; Janina A Longtine; Neal I Lindeman; Charles S Fuchs; Shuji Ogino
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

2.  Epidermal growth factor receptor inhibits colitis-associated cancer in mice.

Authors:  Philip E Dubé; Fang Yan; Shivesh Punit; Nandini Girish; Steven J McElroy; M Kay Washington; D Brent Polk
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

3.  Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.

Authors:  Jamie N Hadac; Alyssa A Leystra; Terrah J Paul Olson; Molly E Maher; Susan N Payne; Alexander E Yueh; Alexander R Schwartz; Dawn M Albrecht; Linda Clipson; Cheri A Pasch; Kristina A Matkowskyj; Richard B Halberg; Dustin A Deming
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

Review 4.  Epigenetics and colorectal cancer.

Authors:  Victoria Valinluck Lao; William M Grady
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-18       Impact factor: 46.802

5.  Novel FAM134B mutations and their clinicopathological significance in colorectal cancer.

Authors:  Farhadul Islam; Vinod Gopalan; Riajul Wahab; Katherine Ting-Wei Lee; Md Hakimul Haque; Afraa Mamoori; Cu-Tai Lu; Robert A Smith; Alfred K-Y Lam
Journal:  Hum Genet       Date:  2017-01-31       Impact factor: 4.132

Review 6.  Colon carcinoma in childhood: review of the literature with four case reports.

Authors:  Gangmi Kim; Seung Hyuk Baik; Kang Young Lee; Hyuk Hur; Byung Soh Min; Chuhl Joo Lyu; Nam Kyu Kim
Journal:  Int J Colorectal Dis       Date:  2012-10-26       Impact factor: 2.571

7.  High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer.

Authors:  Rong Liang; Yan Lin; Chun-Ling Yuan; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Hai-Hong Ye
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

8.  ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.

Authors:  Hoang Dinh Tuy; Hisanori Shiomi; Ken Ichi Mukaisho; Shigeyuki Naka; Tomoharu Shimizu; Hiromichi Sonoda; Eiji Mekata; Yoshihiro Endo; Yoshimasa Kurumi; Hiroyuki Sugihara; Masaji Tani; Tohru Tani
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

Review 9.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Authors:  Shuji Ogino; Charles S Fuchs; Edward Giovannucci
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

10.  Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.

Authors:  Vera Kloten; Michael Rose; Sophie Kaspar; Saskia von Stillfried; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2014-08-04       Impact factor: 4.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.